

ADVISORY COMMITTEE APPLICATION FOR BOARD APPOINTMENT

It is the applicant's responsibility to keep this information current.
To advise the County of any changes please contact Christine Coble
by telephone at 606-5300 or by e-mail at CobleC@leoncountyfl.gov



Applications will be discarded if no appointment is made after two years.

Name: Eric Graban

Date: 14-Jul-2014

Home Phone: (850) 320-6444

Work Phone: (812)272-6362X

Email: eric.graban@reclaim-rx.com

Occupation: FOUNDER/CEO

Employer: RECLAIMRX, LLC

Preferred mailing location: Home Address

Work Address: 901 RIGGINS ROAD, APARTMENT 212

City/State/Zip: TALLAHASSEE FL 32308

Home Address 901 RIGGINS ROAD, APARTMENT 212

City/State/Zip: TALLAHASSEE FL 32308

Do you live in Leon County? Yes If yes, do you live within the City limits? Yes

Do you own property in Leon County? No If yes, is it located within the City limits? No

For how many years have you lived in and/or owned property in Leon County? 1.00 years

Are you currently serving on a County Advisory Committee? No

If yes, on what Committee(s) are you a member?

Have you served on any previous Leon County committees? No

If yes, on what Committee(s) are you a member?

Please indicate your of expertise. If you have experience in more than one field, please check all that apply.

 Finance/Banking Real Estate/Property Development Energy High Performance Materials Biotechnology/Biomedical Aerospace/Aviation**If you are appointed to a Committee, you are expected to attend regular meetings.**

How many days permonth would you be willing to commit for Committee work? 2 to 3

And for how many months would you be willing to commit that amount of time? 6 or more

What time of day would be best for you to attend Committee meetings? Day

(OPTIONAL) Leon County strives to meet its goals, and those contained in various federal and state laws, of maintaining a membership in its Advisory Committees that reflects the diversity of the community. Although strictly optional for Applicant, the following information is needed to meet reporting requirements and attain those goals.

Race: Caucasian

Sex: Male

Age: 42

Disabled? No

District:

In the space below briefly describe or list the following: any previous experience on other Committees; your educational background; your skills and experience you could contribute to a Committee; any of your professional licenses and/or designations and indicate how long you have held them and whether they are effective in Leon County; any charitable or community activities in which you participate; and reasons for your choice of the Committee indicated on this Application.

I HAVE A BACHELORS DEGREE IN BIOLOGY FROM BROWN UNIVERSITY, AND AN MS IN ORGANIC CHEMISTRY FROM OHIO UNIVERSITY. I HAVE WORKED FOR ~15 YEARS IN THE PHARMA/BIOTECH INDUSTRY (ELI LILLY, BAXTER), HOLDING MANAGEMENT POSITIONS IN RESEARCH AND MANUFACTURING. I AM CURRENTLY FOUNDER OF RECLAIMRX, LLC, A START-UP LIFE SCIENCES COMPANY PARTLY BASED IN TALLAHASSEE, AND HAVE A STRONG INTEREST IN SEEING THE LOCAL INFRASTRUCTURE IMPROVE TO BETTER SUPPORT LIFE SCIENCES COMPANIES.

References (you must provide at least one personal reference who is not a family member):

Name: BRENT LIEFFERS Telephone: 8123610902
Address: 9814 TAILWATER DR BLOOMINGTON, IN 47401

Name: Telephone:
Address:

IMPORTANT LEGAL REQUIREMENTS FOR ADVISORY COMMITTEE MEMBERSHIP

AS A MEMBER OF AN ADVISORY COMMITTEE, YOU WILL BE OBLIGATED TO FOLLOW ANY APPLICABLE LAWS REGARDING GOVERNMENT-IN-THE-SUNSHINE, CODE OF ETHICS FOR PUBLIC OFFICERS, AND PUBLIC RECORDS DISCLOSURE. THE CONSEQUENCES OF VIOLATING THESE APPLICABLE LAWS INCLUDE CRIMINAL PENALTIES, CIVIL FINES, AND THE VOIDING OF ANY COMMITTEE ACTION AND OF ANY SUBSEQUENT ACTION BY THE BOARD OF COUNTY COMMISSIONERS. IN ORDER TO BE FAMILIAR WITH THESE LAWS AND TO ASSIST YOU IN ANSWERING THE FOLLOWING QUESTIONS, YOU MUST COMPLETE THE ORIENTATION PUBLICATION www.leoncountyfl.gov/bcc/committees/training.asp BEFORE YOUR APPLICATION IS DEEMED COMPLETE.

Have you completed the Orientation? Yes
Are you willing to complete a financial disclosure form and/or a background check, if applicable? Yes
Will you be receiving any compensation that is expected to influence your vote, action, or participation on a Committee? No
If yes, from whom?
Do you anticipate that you would be a stakeholder with regard to your participation on a Committee? No
Do you know of any circumstances that would result in you having to abstain from voting on a Committee due to voting conflicts? MY COMPANY COULD BENEFIT FROM HAVING WET LAB SPACE AVAILABLE FOR STAFF-UP COMPANIES IN TALLAHASSEE
If yes, please explain.
Do you or your employer, or your spouse or child or their employers, do business with Leon County? No
If yes, please explain.
Do you have any employment or contractual relationship with Leon County that would create a continuing or frequently recurring conflict with regard to your participation on a Committee? No
If yes, please explain.
All statements and information provided in this application are true to the best of my knowledge.

Signature: Eric Graban

This application was electronically sent: 7/14/2014 1:32:39PM

ERIC M. GRABAN

901 Riggins Rd., Apt 212 Tallahassee, FL 32308
Phone: (812) 272-6362

PROFESSIONAL SUMMARY

Highly motivated leader with a proven record in developing and implementing business systems and technical solutions that meet or exceed customer expectations in delivering business results.

ENTREPRENEURSHIP

Founder/CEO, ReclaimRx, LLC

10/2010 – present

ReclaimRx is developing technology to allow protein structure measurement in a way that is currently not available. Our technology will help reduce risk for companies developing biotech drugs, decrease the time required to get biotech drugs to market, and help researchers understand protein interactions that can cause diseases. We are partnering with research groups at UMass and Indiana University to finish development of our technology, and anticipate revenue generation in Q3 of 2014.

- Recipient of LCRDA Technology Grant in 2014
- www.Reclaim-Rx.com

Scientific Advisor, Kailash Biosciences

6/2013 - present

Kailash is developing compound libraries to help researchers identify new uses for existing drugs. Researchers currently use a technique called High Throughput Screening (HTS) that allows researchers to screen up to 100,000+ compounds when trying to identify drug candidates for diseases being studied. A recent trend is to include samples from approved drugs in these studies, as this would significantly simplify regulatory hurdles needed to gain market approval. However, many thousands of approved drugs are not available for HTS studies. Kailash has developed a unique business model that will allow them to be the first provider of these compounds for HTS studies. My responsibilities:

- Provide scientific guidance regarding the chemistry of compounds to be included in the library, and regarding analytical and manufacturing activities needed to support the business
- Initiate and maintain contact with potential clients to identify customers ahead of product release, and to gather market analysis to ensure product offering matches market needs
- <http://www.kailashbio.com/>

PHARMACEUTICAL MANUFACTURING

Director, Aseptic Manufacturing, Baxter Pharmaceutical Solutions

6/2012 – 4/2013

The Baxter Bloomington plant is a contract pharmaceutical manufacturing facility that has over 50 clients and produces over 150 drug products. I was an interim director for all aseptic

manufacturing operations, with responsibility for 3 manufacturing buildings and over 250 employees.

Manager, Aseptic Manufacturing, Baxter Pharmaceutical Solutions 12/2009 – 6/2012

Before this, I led a manufacturing building that generated over \$100 million in product in 2011 (including multiple high profile new products). My responsibilities and accomplishments included:

- Leadership of a multi-disciplinary building management team that included a technical support group and a quality assurance group. Over 100 employees directly support the building.
 - Successfully led building through multiple PAI and annual audits from US (FDA), EU (EMA), Japan (JPAL), UK (MHRA), Brazil (ANVISA), and others
 - Led multiple site projects that are interdisciplinary in nature, including projects to improve inventory control and equipment effectiveness
- Innovations in and improvement of key building deliverables, including doubling on-time delivery, reducing defect rates by >50%, and implementing multiple cost savings and lean manufacturing initiatives.
- Direct interface with clients to ensure client satisfaction.
 - Restored critical relationships with three primary clients via improved communication and performance in on-time delivery and batch deviation rates. This effort resulted in all three clients extending their contracts with Baxter.

Supervisor, Technical Services, Baxter Pharmaceutical Solutions 8/2007 - 12/2009

In this role, I led a group of 8-13 engineers and scientists who provided day-to-day support for 8 commercial-scale aseptic filling/lyophilization lines:

- The group I inherited had been without a leader for ~9 months. My primary goal was to improve the technical proficiency of the group.
 - Implemented training program to increase technical capability of group
 - Initiated and implemented a recruiting program to identify high-caliber candidates from Notre Dame University and Purdue University; successfully identified and hired our top 2 candidates from each school
 - Successfully improved site perception and expectations for the group
- Drove development and implementation of business systems to allow for improved tracking of performance for key manufacturing investigation activities (OCR, EX).

Manager, Technical Services, Eli Lilly & Co. 10/2004 - 6/2007

In this role, I led a group of 25 employees (BS/MS/PhD chemists & chemical engineers, technicians) that was responsible for providing technical oversight of day-to-day chemical manufacturing operations of Active Pharmaceutical Ingredients and intermediates.

Responsible for delivering a laboratory program targeted to generate over \$5 million in annual savings. Support for various cGMP based inspections (including FDA and internal):

- Co-developed a “core competencies” training course for TS to instill basic data analysis and investigation principles; hands-on approach was received well, with program being expanded to other Lilly sites

- Initiated program that delivered over 90% reduction in group cGMP documentation backlog
- Initiated and led an effort to improve efficiency of preparation of batch records and include this activity in site metrics (OSSCE); increased on-time delivery from less than 25% to greater than 90%
- Drove successful development and implementation of process improvement to increase production yield, resulting in ~\$1.5 million in annual savings
- Provided technical guidance for multiple technical issues and projects in my group

Six Sigma Greenbelt, Technical Services, Eli Lilly & Co.

03/2006 - 6/2007

Concurrent to Team Leader position, I was responsible for leading and executing a six sigma project to optimize production campaign preparation activities:

- Project delivered ~\$150,000 in annual savings, exceeding the targeted goal of \$100,000 in annual savings
- Successfully streamlined campaign preparation activities via identification and removal of redundant activities
- Success included change in site culture to allow removal of redundant business oversight systems

Gemcitabine Molecule Technical Steward, Eli Lilly & Co.

01/2003 - 09/2004

Responsible for strategic oversight of the technical agenda for all 7 chemical process steps for Gemcitabine HCl, and coordinating this agenda with multiple fill/finish customer sites:

- Initiated and maintained monthly technical meeting involving network manufacturing sites in the US and France, allowing rapid and often proactive resolution of technical and supply issues
- In response to a multi-batch contamination event, led multi-functional team to rapidly identify and implement testing plan that resulted in recovery of product worth ~\$20 million
- Initiated and led a multi-site effort to harmonize network acceptance criteria for Gemcitabine HCl, resulting in ~\$1 million in savings as batches deemed acceptable on the sending site are no longer rejected by the receiving site
- Led numerous multi-site technical investigations

Organic Chemist, Technical Services, Eli Lilly & Co.

07/2001 - 12/2002

In this role, I was the primary technical support for production scale manufacture of API & intermediates for Zyprexa, Gemzar (parenteral API), and Seromycin:

- Led high-visibility site-to-site transfer of 2 API intermediate processes to ensure continued market supply of blockbuster drug; international project involved 3 third party manufacturers and 2 Lilly sites located in the US and Europe

- Developed and implemented solution to address historical 50% reject rate for API intermediate process resulting in ~\$0.5 million in savings per production campaign
- In response to a contamination event, led multi-functional team to identify and implement testing plan that resulted in recovery of product worth ~\$5 million

SPECIALTY CHEMICAL MANUFACTURING

Development Chemist, Process R&D, OSi Specialties, Inc.

01/1998 - 06/2001

As an R&D chemist, I was responsible for the process development of new products from lab to commercial scale, technical troubleshooting for over 30 products in production, process improvements/optimization, developing methods for recovering reject material, and cost analysis for products & production processes:

- Scaled up 19 new products from bench top to commercial scale including three 4000-gallon preps and three 440-gallon preps
- Designed and implemented a new hydrosilation catalyst that:
 - Significantly reduced batch times by increasing catalyst activity and stability while reducing undesired side reactions; saved \$70,000 in 2000
- Invented and developed breakthrough technology allowing for significant color reduction in Silwet® Copolymer products

Advanced Technician, Process R&D, OSi Specialties, Inc.

10/1994 - 12/1997

Worked with Ph.D. Chemists to design and execute experimental programs

ENVIRONMENTAL SERVICES

Analyst, Extractions Lab, Kemron Environmental Services

05/1993 - 09/1994

EDUCATION

M.S. Chemistry 08/2002
Ohio University, Athens, Ohio

Research Program: Stereoselective Diazocoupling of Ethyldiazoacetate Using $(\text{PPh}_3)_3\text{RuCl}_2$
Research Advisor: Dr. Frederick Lemke

B.S. Biology 05/1993
Brown University, Providence, Rhode Island

PUBLICATIONS

E. M. Graban, F. R. Lemke, "Stereoselective Generation of Cis or Trans Olefins from the $\text{RuCl}_2(\text{PPh}_3)_3$ -Catalyzed Diazocoupling of Ethyldiazoacetate." *Organometallics* 2002, 21, 3823 – 3826.

Schilling, C. L.; Burns, P. J.; Ritscher, J. S.; Bowman, M. P.; Childress, T. E.; Powell, M. R.; **Graban, E. M.** "Hydrosilation Reaction Process with Recycle." U.S. Patent No. 6,015,920; January 18, 2000.

Bowman, M. P.; Burns, P. J.; Childress, T. E.; Sheridan, R. E.; Turner, S. M.; Young, W. T.; **Graban, E. M.**; Malson, E. E.; McIntyre, J. L.; Powell, M. P.; Hartman, K. W.; Magri, S.; Trotta, G. "Applications of Direct Synthesis $\text{HSi}(\text{OCH}_3)_3$," in *Silicon Chem. Ind. IV* [Conf.]; Oeye, Harald A., Ed.; Norwegian University of Science and Technology: Trondheim, Norway, 1998, pp. 295-306.

PRESENTATIONS

Graban, E. M., "Factors Affecting the Transition Metal Catalyzed Dehydrocondensation Reaction"; Annual Colloquium on the Hydrosilation Reaction; OSi Specialties, Inc. Internal Symposium, Tarrytown, NY; June 1999.

Graban, E. M., "Stereoselective Generation of *cis* or *trans* Olefins from $\text{RuCl}_2(\text{PPh}_3)_3$ Catalyzed Diazocoupling of Ethyldiazoacetate"; American Chemical Society National Meeting, New Orleans, LA; March, 2003.

AWARDS

Eli Lilly & Company "Changing the World." Received in recognition for leading the successful site-to-site transfer of 2 critical manufacturing process intermediates from 1 third party to 2 others while executing a contingency campaign at a 4th site. 2002.